scholarly journals Ear Acupuncture Therapy for Masticatory Myofascial and Temporomandibular Pain: A Controlled Clinical Trial

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Luciano Ambrosio Ferreira ◽  
Eduardo Grossmann ◽  
Eduardo Januzzi ◽  
Rafael Tardin Rosa Ferraz Gonçalves ◽  
Fernando Antonio Guedes Mares ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Acupuncture Therapy ◽  
Ear Acupuncture ◽  
Synergistic Action ◽  
Auricular Acupuncture ◽  
Controlled Clinical Trial ◽  
Occlusal Splint ◽  
Short Term ◽  
Experienced Pain ◽  
Temporomandibular Pain

Ear acupuncture works by reducing painful sensations with analgesic effect through microsystem therapy and has been demonstrated to be as effective as conventional therapies in the control of facial pain. This clinical trial aimed to evaluate the adjuvant action of auricular acupuncture through an observation of the evolution of temporomandibular and masticatory myofascial symptoms in two groups defined by the therapies elected: auricular acupuncture associated with occlusal splint (study) and the use of the occlusal splint plate alone (control). We have selected 20 patients, who were randomly allocated into two groups of ten individuals. Symptoms were evaluated in five different moments, every seven days. We analyzed the orofacial muscle and joint palpation in order to measure the intensity of the experienced pain. Both groups showed a statistically significant decrease in muscle and joint symptoms (p<0.05). However, comparisons between the groups showed an expressive and significant reduction of symptomatology in the study group (p<0.05) already on the first week of therapy. According to the results, to the methodological criteria developed and statistical analysis applied, the conclusion is that auricular acupuncture therapy has synergistic action on conventional occlusal splint treatment. It was demonstrated to be effective in the reduction of symptoms in the short term.

scholarly journals Pressure Algometry Evaluation of Two Occlusal Splint Designs in Bruxism Management-Randomized, Controlled Clinical Trial

2021 ◽  
Vol 10 (11) ◽  
pp. 2342
Author(s):  
Bartosz Dalewski ◽  
Agata Kamińska ◽  
Paweł Kiczmer ◽  
Krzysztof Węgrzyn ◽  
Łukasz Pałka ◽  
...  
Keyword(s):  
Pain Threshold ◽  
Pressure Pain Threshold ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Occlusal Splint ◽  
Short Term ◽  
Randomized Controlled ◽  
Canine Guidance ◽  
Medical University

The aim of this pilot study was to evaluate the short-term effectiveness of two different occlusal devices and their impact on the pressure pain threshold (PPT) values among patients who reported to the Dental Prosthetics Outpatient Clinic of Pomeranian Medical University (Szczecin, Poland) and who were diagnosed with probable bruxism. Two groups were formed (A and B) to which patients were assigned randomly. Each group used a different occlusal splint for bruxism management. The occlusal appliance by Okeson, or the bimaxillary splint, was used overnight by each patient for 30 days of the study. The PPT was measured twice, at the first visit and after 30 days of using each occlusal device, with Wagner Paintest FPX 25 algometer. Bruxism was diagnosed based on data from the patient’s medical history and from the physical examination. Nocturnal Bruxism Criteria according to the International Classification of Sleep Disorders (Third Edition) was used for the patient’s evaluation. Results: similar pain factor (PF) reduction was observed in both the examined groups, regardless of the device used; canine guidance and no guidance were similarly effective in terms of increasing pain resilience.

­Evaluation of Immediate and Short-Term Efficacy of DualStim Therapy with and without Intracavernosal Umbilical Cord-Derived Wharton’s Jelly in Patients with Erectile Dysfunction: Study Protocol for a Pilot Randomised Controlled Trial

2020 ◽  
Author(s):  
Ashim Gupta ◽  
Hugo C. Rodriguez ◽  
Kristin Delfino ◽  
Howard J. Levy ◽  
Saadiq F. El-Amin III ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Erectile Dysfunction ◽  
Umbilical Cord ◽  
Erectile Function ◽  
Wharton’S Jelly ◽  
Post Treatment ◽  
Controlled Clinical Trial ◽  
Short Term ◽  
Wharton's Jelly ◽  
Term Efficacy

Abstract Background Erectile Dysfunction (ED) affects a significant portion of the U.S. population and causes negative psychological burdens that affects men and their partner’s quality of life and satisfaction. Extracorporeal shock therapy (ESWT) utilizing focused ESWT (fESWT) and radial ESWT (rESWT) in Low-intensity shock wave therapy (LSIWT) has been used to treat ED with some success. Wharton’s Jelly (WJ) is a biologic substance with large amounts of stem cells, growth factors, cytokines and extracellular components. The use of simultaneous fESWT and rESWT (DualStim Therapy) combined with WJ have potential uses in ED that may have advantages over current treatments. Methods A randomized, single-blinded, controlled clinical trial will be conducted to evaluate the efficacy and safety of DualStim Therapy and ICIs of WJ in moderate to severe ED. A total of 60 patients with moderate to severe ED will be enrolled and treated with DualStim Therapy with intracavernosal injection (ICIs) of WJ or saline for a period of 7 weeks. The International Index of Erectile Function – Erectile Function (IIEF-EF) score will be used to gauge the treatment related changes in relation to the subject’s baseline. The scores will be recorded at baseline and compared to follow-ups 1,3 and 6 months post-treatment. Any Adverse events (AEs) or severe AEs will be recorded in the corresponding case report forms (CRFs). Sexual Encounter Profile (SEP), as well as the Global Assessment Questionnaire (GAQ) and the Erection Hardness Score (EHS) will be used to determine the sexual activity improvement from baseline leading to optimal penetration at follow-ups 1,3 and 6 months post-treatment.Discussion This clinical trial is a feasibility study to determine the immediate and short-term efficacy of DualStim Therapy, with and without ICIs of formulated umbilical cord-derived WJ to improve and/or restore erectile function in patients with moderate to severe ED. This study will also provide insight into the safety and efficacy of WJ. We anticipate clinically significant improvement in patients suffering from moderate and severe ED treated with DualStim therapy with WJ compared to their baseline and DualStim with saline.Trial registration Registered on ClinicalTrials.gov; the trial number is NCT04424394

Effect of Short-Term Training on Reaching Behavior in Infants: A Randomized Controlled Clinical Trial

2015 ◽  
Vol 48 (2) ◽  
pp. 132-142 ◽  
Author(s):  
Andréa Baraldi Cunha ◽  
Michele A. Lobo ◽  
Elena Kokkoni ◽  
James C. Galloway ◽  
Eloisa Tudella
Keyword(s):  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Short Term ◽  
Randomized Controlled

scholarly journals Short-Term Effect of a New Oral Sodium Hyaluronate Formulation on Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Diseases ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 26
Author(s):  
Arrigo F. G. Cicero ◽  
Nicolò Girolimetto ◽  
Crescenzio Bentivenga ◽  
Elisa Grandi ◽  
Federica Fogacci ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Knee Osteoarthritis ◽  
Sodium Hyaluronate ◽  
Womac Score ◽  
Term Effect ◽  
Controlled Clinical Trial ◽  
Short Term ◽  
Double Blind ◽  
Oral Supplementation ◽  
Short Term Effect

Objective: the aim of this pilot study was to test the short-term effect of oral supplementation with a sodium hyaluronate with a large spectrum of molecular weights (FS-HA®) on the symptoms and functionality of knee osteoarthritis (OA). Methods: 60 subjects affected by clinical and/or radiological diagnosis of symptomatic knee OA were consecutively enrolled in a randomized, double blind, placebo-controlled, clinical trial. At randomization visit, at day 28 (visit 2), and day 56 (visit 3), the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC), the Lequesne Functional Index (LFI) and the Visual Analogue Scale (VAS) for pain (VAS-p) were administered to the enrolled patients. Then, patients were asked how many times they used rescue medications (non-steroidal antinflammatory drugs–NSAIDs and/or anti-pain drugs) during the previous 4 weeks. Finally, the range of knee joint motion (ROM) was also instrumentally measured. Results: In FS-HA® treated subjects, VAS-p, pain and total WOMAC score, LFI and ROM significantly improved compared to the baseline values (p < 0.05). At 60 days, the VAS-p and the pain WOMAC score were significantly lower after FS-HA® treatment when compared with placebo as well (p < 0.05). The FS-HA® treated subjects significantly reduced the weekly use of NSAIDs and/or antipain drugs when compared to the placebo-treated ones (p < 0.05). Conclusion: the oral supplementation with a FS-HA® characterized by a large spectrum of molecular weight was associated with a short-term improvement in symptomatology and functionality of osteoarthritis-affected knees, and associated with a reduction in the use of NSAIDS and anti-pain drugs.

Sign in / Sign up

Export Citation Format

Share Document